Common use of Biological Samples Clause in Contracts

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.12.2

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a..

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., stool samples, blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient Trial Subject care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a..

Biological Samples. If so specified in the Protocol, Institution Provider and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., stool samples, blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient Trial Subject care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.12.2.1

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects Study subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.(g)

Biological Samples. If so specified in the Protocol, Institution Provider and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.

Biological Samples. If so As specified in the Protocol, Institution Provider and Principal Investigator may will collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) (“Biological Samples”) obtained from Trial Subjects for purposes of the Trial, and, provided that the Trial Subject has given his/her prior written informed consent, for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomicpharmacogenomics, or biomarker testing (“Biological Samples”)testing. a.12.3

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.11.3

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.11.2

Biological Samples. If so specified in the ProtocolProtocol and the informed consent document, Institution and Principal Investigator may collect and provide to Covance, Sponsor or its their designee biological samples obtained from Study subjects (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient Study subject care or safety monitoring, including such as pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.28.

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.Biologické vzorky Pokud tak stanoví protokol, zdravotnické zařízení a hlavní zkoušející mohou shromažďovat a poskytovat zadavateli nebo osobě jím určené biologické vzorky (např. krev, moč, tkáň, sliny apod.) získané od subjektů klinického hodnocení pro testy, které nejsou přímo spojené s péčí o pacienty nebo sledováním bezpečnosti, včetně farmakokinetických, farmakogenomických nebo biomarkerových testů (dále jen „biologické vzorky“).

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.11.2

Biological Samples. If so specified in the Protocol, Institution Provider and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects Study subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.(g)

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.11.2

Biological Samples. If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee biological samples (e.g., blood, urine, tissue, saliva, etc.) obtained from Trial Study Subjects for testing that is not directly related to patient care or safety monitoring, including pharmacokinetic, pharmacogenomic, or biomarker testing (“Biological Samples”). a.Pracovisko skúšania berie na vedomie a súhlasí, že ak skúšajúci do kľúčového dátumu zaraďovania nezaradí do skúšania aspoň jeden